Idursulfase beta

【Suzhou, China, 3 August 2026】– CANbridge Pharmaceuticals Inc. (“CANbridge” or the “Company”, Stock Code: 1228.HK), a global biopharmaceutical company focused on rare diseases, is committed to the research, development and commercialization of innovative therapies. The Company announced that Pauline Li, MD has rejoined CANbridge as Chief Medical Officer. The reappointment marks an important step to strengthen its research and developmental capabilities and step up its readiness to refresh its pipeline programs, as CANbridge continues to pivot global innovation strategies. Before her personal sabbatical from the industry, Dr. Li served as Senior Vice President of Clinical Development and Operations and briefly Chief Medical Officer between 2022 and 2024. Despite the challenges during the Covid pandemic, Dr. Li successfully led the implementation of three CANbridge sponsored clinical trials, including two registrational studies. Her team also played a meaningful role in assisting on-schedule local patient enrollment of a global pivotal study in China sponsored by a CANbridge partner. The dedicated work of her team led to the completion of the Gaucher CAN103 registrational trial in record time and eventual market approval of Gaurunning® by the NMPA in May 2025. Dr. James Xue, Founder, Chairman and Chief Executive Officer of CANbridge, said: “We are so delighted that Pauline has rejoined CANbridge and taking on such a critical leadership role at a very important moment. Her extensive international clinical development experience and expertise, her industry track record and her strong belief in CANbridge’s mission makes her a timely addition to our leadership team to implement the Company’s strategy to become a global value creator in rare disease innovation. Prior to joining CANbridge, Pauline Li held roles as Medical Director and Executive Director of Clinical Operations at various pharmaceutical companies including Suzhou Connect Biopharmaceuticals, Roche, J&J, Bayer, Takeda China, Servier and Haihe Pharmaceutical, accumulating extensive experience in clinical development, clinical operations and medical affairs. Before entering the pharmaceutical industry, she worked as a practicing cardiologist at Beijing Fuwai Heart Disease Hospital for 6 years. Pauline Li holds an MBA from Peking University, a Master’s Degree in Internal Medicine from Peking Union Medical College, and a Bachelor’s Degree in Clinical Medicine from Beijing Medical University. About CANbridge CANbridge Pharmaceuticals Inc. (Stock Code: 1228.HK) was founded in 2012 and listed on the Main Board of HKEX in 2021. The Company is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases. As of December 31, 2025, the Company has a comprehensive pipeline of 7 drug assets targeting prevalent rare diseases that have high unmet needs and significant market potential. The robust pipeline includes 3 marketed products (Hunterase®, Livmarli®, Gaurunning®) and 1 drug candidate at the late clinical stage, covering biologics, small molecules and gene therapies. In the rare disease area, the Company currently has seven biologic and small molecule product candidates. These include MPS II (Hunter syndrome) and other lysosomal storage disorders (LSDs), complement-mediated disorders, hemophilia A, metabolic disorders and rare cholestatic liver diseases including Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Furthermore, CANbridge is investing in the R&D of next-generation gene therapy technologies, which will provide novel, potentially curative therapies for rare genetic diseases with limited treatment options. To support the research, development and commercialization of its pipeline, the Company has built a global partner network including, but not limited to, WuXi AppTec, WuXi Biologics, Baheal Medical, GC Pharma, Mirum, Privus and Scriptr Global.

中国苏州，2026年8月3日——北海康成制药有限公司（以下简称“北海康成”，股票代码：1228.HK），是一家在中国领先并专注罕见疾病领域的全球化生物制药公司，致力于创新疗法的研究、开发和商业化。公司今日正式宣布，李萍女士重返北海康成并担任首席医学官。此次重新任命将进一步夯实公司临床研发实力，加速管线项目迭代升级，助力北海康成持续推进全球创新战略布局。 2022至2024年，李萍女士在北海康成先后担任临床开发与运营高级副总裁，并短暂兼任首席医学官。即便面临新冠疫情等多重挑战，她仍牵头落地了三项公司自主发起的临床试验，其中包含两项注册性临床研究；其团队同步配合公司海外合作伙伴，顺利完成一项全球关键研究的中国区域受试者入组工作。依托团队高效专业的推进，提前完成戈谢病药物CAN103注册试验的全部研究工作，对应产品戈芮宁®也于2025年5月获批上市。 我们由衷欢迎李萍女士重返北海康成，在公司全球战略发展的关键阶段扛起核心管理重任。她拥有丰富的国际化临床开发经验、亮眼的行业落地成果，同时高度认同北海康成深耕罕见病领域的企业使命。她的及时回归将为管理团队补齐关键力量，支撑公司落地战略目标，打造全球罕见病创新价值平台。 加入北海康成前，李萍女士历任多家跨国药企与本土生物企业医学总监、临床运营执行总监，任职企业涵盖苏州康乃德生物、罗氏、强生、拜耳、武田中国、施维雅、海和制药，在临床开发、临床运营、医学事务全链条积累了深厚实操经验。投身医药产业前，她在北京阜外心血管病医院从事心血管专科临床诊疗工作六年，具备扎实的一线临床执业背景。 李萍女士拥有北京大学工商管理硕士学位、北京协和医学院内科硕士学位及北京医科大学临床医学学士学位。 向上滑动阅览 北海康成制药有限公司（股份代号：1228.HK）成立于2012年，于2021年在港交所主板上市。作为中国领先的专注于罕见疾病的全球化生物制药公司，公司致力于创新疗法的研究、开发与商业化。截至2025年底，针对拥有巨大市场潜力的部分最常见的罕见病，公司已打造由多个药物资产组成的全面产品线，包括3个已上市产品（海芮思®、迈芮倍®、戈芮宁®）及1个处于临床后期阶段的候选药物，涵盖生物制剂、小分子及基因疗法。在罕见病领域，公司目前拥有七种生物制剂及小分子产品针对多种适应症,包括MPS II（即亨特综合征）及其他溶酶体贮积病(LSD)、补体介导疾病、A型血友病、代谢紊乱以及罕见胆汁淤积性肝病，包括阿拉杰里综合征（ALGS）及进行性家族性肝内胆汁淤积症(PFIC)。此外，北海康成积极投入新一代基因治疗技术研发，针对治疗方案有限的罕见遗传病，开发具备潜在治愈性的全新创新疗法。为支撑上述产品管线的研发与商业化落地，公司构建了覆盖全球的合作伙伴网络，包括但不限于药明生物、百洋医药、GC Pharma、Mirum、Privus和Scriptr Global 等。 前瞻性声明：本文中作出的前瞻性陈述仅与本文作出陈述之日的事件或信息有关。除非法律要求，否则我们不承担公开更新或修改任何前瞻性陈述的义务，无论是由于新信息、未来事件或其他原因，在做出陈述的数据之后或反映意外事件的发生情况。您应完整阅读本文，并了解我们未来的实际结果或表现可能与我们的预期存在重大差异。在本文中，我们或我们的任何董事或我们公司的意图的陈述或引用均在本文发表之日作出。这些意图中的任何一个都可能随着未来的发展而改变。 联系我们： 投资者关系： ir@canbridgepharma.com